Thanks for your question and apologies for the delay in getting back to you.
Earlier this month (3 October) the National Institute for Health and Care Excellence (NICE) announced its decision to provisionally reject atezolizumab with nab-paclitaxel.
This is a draft recommendation and it is now out for consultation until later this month and then a final decision will be made on its use later this year. Our response to this announcement can be found here.
We are currently looking to hear from people who have experience of atezolizumab with nab-paclitaxel for untreated locally advanced or metastatic triple negative breast cancer, whose cancers produce the marker PD-L1. This will help inform our response to the consultation, to highlight why it’s crucial that a positive decision is made on the use of this important treatment on the NHS. People can share their experiences with us here.
Please don’t hesitate to get in touch with us if you have any questions.
I work in the Policy and Campaigns Team at Breast Cancer Care.
Atezolizumab is currently being considered by the National Institute for Health and Care Excellence (NICE) to be made available on the NHS in England for treating previously untreated, locally advanced or metastatic, triple negative, PD-L1 positive breast cancer.
We are gathering evidence to contribute to NICE's patient carer groups' submissions and we’d like to speak to anybody who is being or has been treated with atezolizumab, to help inform our response on what access to this drug would mean to women with secondary breast cancer.
We’re looking for responses by 21 March.
If you’re able to help, please email email@example.com